Guides
12 pages in this section, most recently updated September 4, 2026.
- 01
The tirzepatide titration schedule, step by step, with dates
What the Zepbound and Mounjaro labels say about starting at 2.5 mg, moving up in 2.5 mg steps, and which doses count as maintenance. Plus a planner that turns the rules into calendar dates.
Updated September 4, 2026
- 02
Missed a tirzepatide dose? The 96-hour rule and the 72-hour rule
Exactly what the Zepbound and Mounjaro labels say about a late dose, a skipped dose, and changing your injection day, with worked examples and a helper that applies the rules to your times.
Updated September 4, 2026
- 03
Units, mL and mg: reading a compounded tirzepatide vial without a dosing error
Why a compounded tirzepatide dose has to be recalculated for every vial, how insulin-syringe units relate to milligrams, what the brand concentrations are, and what FDA says about dosing errors.
Updated September 4, 2026
- 04
Tirzepatide side effects by dose: the label table, read properly
Adverse reaction rates for 5, 10 and 15 mg versus placebo from the Zepbound label, what the label says about timing, discontinuation rates, and how to read percentages without scaring yourself.
Updated September 4, 2026
- 05
How tirzepatide works, in the words the label uses
GIP and GLP-1 receptor agonism, a 5-day half-life, steady state after four weeks, and what those facts mean for the weekly schedule and for stopping.
Updated September 4, 2026
- 06
Storing tirzepatide: the 21-day, 30-day and 4-dose limits
What the Zepbound and Mounjaro labels allow for single-dose pens and vials, multi-dose vials and KwikPens, in the fridge and out of it, and what to do with a frozen or heated dose.
Updated September 4, 2026
- 07
The first four weeks at 2.5 mg: what the label says that dose is for
Why tirzepatide starts at a dose the label calls non-therapeutic for maintenance, what happens to drug levels over the first four injections, and what the trials required before the first increase.
Updated September 4, 2026
- 08
The SURMOUNT trials in numbers
SURMOUNT-1 through 5 and SURMOUNT-OSA: who was enrolled, how long, what changed, with confidence intervals and PubMed ids. The page to check any tirzepatide statistic against.
Updated September 4, 2026
- 09
Stopping tirzepatide: what SURMOUNT-4 measured
The one trial that randomised people to keep taking tirzepatide or switch to placebo after 36 weeks, its regain numbers, what the label says about maintenance, and what the data cannot tell you about tapering.
Updated September 4, 2026
- 10
Tirzepatide for obstructive sleep apnea: the indication, the dosing and the trial
What Zepbound's December 20, 2024 OSA approval covers, why the maintenance dose is 10 or 15 mg, and the SURMOUNT-OSA results with and without PAP therapy.
Updated September 4, 2026
- 11
Tirzepatide warnings and contraindications, in plain language
The boxed warning, the two contraindications, and each warning in section 5 of the Zepbound label, with the label's own numbers where it gives them and what changed in 2026.
Updated September 4, 2026
- 12
Compounded tirzepatide and the FDA: the shortage timeline and what it means now
The dates that governed compounded tirzepatide, from the December 2022 shortage listing to the December 19, 2024 declaratory order and the February and March 2025 enforcement deadlines, plus FDA's adverse event counts.
Updated September 4, 2026